BlackRock
-
$200M investment to advance clinical programs for Ambrx
The San Diego-based biopharma firm has several oncology therapies in development and has partnered in the past with the likes of Astellas, BeiGene and Bristol-Myers Squibb.
-
Kronos Bio raises $155M in private financing to advance lead leukemia drug into registration study next year
The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Devices & Diagnostics, MedCity Influencers
Orthopedic device maker Smith & Nephew: BlackRock now top investor
The world’s largest asset management firm, BlackRock Inc., boosts its position in Smith & Nephew […]